Related Experiment Video
Updated: Apr 24, 2026
05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
38.9K
Pharmacogenes Associated with Suicidal Behavior: Addressing a Potential Therapeutic Window
Janette Andrea Becerra López1,2, Alma Delia Genis Mendoza1,3,4, Humberto Nicolini1
1Laboratory of Genomics of Psychiatric and Neurodegenerative Diseases, National Institute of Genomic Medicine, 14610 Mexico City, Mexico.
Actas Espanolas De Psiquiatria
|April 23, 2026
Summary
Pharmacogene variants, like ABCB1 and FKBP5, are linked to suicidal behavior. Understanding these genetic links can improve psychotropic drug response and suicide prevention strategies.
Area of Science:
- Genetics
- Psychiatry
- Pharmacology
Background:
- Suicide rates are increasing in Mexico.
- Suicidal behavior has a known genetic component.
- Pharmacogenes are being investigated for their role in suicide risk.
Purpose of the Study:
- To review existing literature on pharmacogenes and suicidal behavior phenotypes.
- To examine the role of pharmacogenes in pharmacological treatment response for suicidal behavior.
- To identify potential shared genetic mechanisms underlying different suicide phenotypes.
Main Methods:
- Literature review of studies investigating pharmacogenes and suicidal behavior.
- Analysis of identified pharmacogenes, including ABCB1 and FKBP5.
- Examination of genetic variants associated with suicide attempts, completed suicides, and treatment response.
Main Results:
- Variants in ABCB1 and FKBP5 are frequently observed in suicide attempt and completed suicide phenotypes.
- Certain pharmacogene variants may lead to reduced drug efficacy or worsened symptoms.
- Overlapping variants exist between suicidal behavior and altered psychotropic drug response, suggesting increased genetic vulnerability.
Conclusions:
- Shared genetic mechanisms may underlie different suicide phenotypes.
- Pharmacogenomic insights can inform personalized treatment approaches for suicidal behavior.
- Further research, particularly in the Mexican population, is needed to validate findings and advance precision medicine in suicide prevention.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
155
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155
01:28Human Genetics
2.0K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
2.0K
01:29Pharmacogenomics: Identification of New Drug Targets
113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
01:27Principles of Pharmacogenetics: Types of Genetic Variants
134
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
134
01:27Pharmacogenetics of Drug Metabolism: Overview
187
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
187